GGGGCC hexanucleotide repeat expansions in neurodegenerative disease
GGGGCC hexanucleotide repeat expansions in neurodegenerative disease
批准号:
8416082
负责人:
Rosa Rademakers
金额:
$36.19万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-30 至 2017-06-30
关键词:
AffectAgeAge-YearsAlternative SplicingAmyotrophic Lateral SclerosisApplications GrantsBiological AssayBloodBrainBrain regionCandidate Disease GeneCell Culture TechniquesCell LineCellsCessation of lifeChromosomesClinicClinicalClinical PathologyCollaborationsCollectionCustomDNADataDevelopmentDiseaseFamilyFrontotemporal DementiaFrontotemporal Lobar DegenerationsFunctional RNAGene ExpressionGene Expression ProfileGenesGeneticGenetic ResearchGenetic TranscriptionGenomeGenotypeHistocompatibility TestingHumanHuman GenomeIn VitroLeadLengthLinkMessenger RNAModelingMolecularMutationNeurodegenerative DisordersNuclear RNAOnset of illnessPathogenesisPathologyPatientsPhenotypePlayRNARNA Sequence AnalysisRNA SequencesRNA SplicingRNA-Binding ProteinsRegression AnalysisReportingRiskRisk FactorsRoleSamplingSeverity of illnessSouthern BlottingSpinal CordSpliced GenesSymptomsTestingTimeTissuesVariantWorkbrain tissueclinical phenotypecohortdensitydesignfollow-upfrontal lobegain of functiongenome wide association studyhuman tissueinduced pluripotent stem cellknock-downlymphoblastmutation carriernovelpatient populationprotein TDP-43
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The last few years have been extremely exciting for genetic research into the understanding of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two closely related devastating neurodegenerative disorders with overlapping clinical, genetic and neuropathologic features. In 2011, we identified a GGGGCC hexanucleotide repeat expansion in the non-coding region of C9ORF72 as the long- sought cause of FTD and ALS linked to chromosome 9p, further demonstrating the clinical and molecular overlap between these diseases. Genetic studies now suggest that this repeat expansion is the most common cause of familial FTD and ALS, explaining 10-20% of FTD and 25-40% of ALS families worldwide. This mutation also explains the disease in 1-5% of sporadic patients. What determines whether mutation carriers develop FTD and/or ALS and whether symptoms occur as early as 30 years of age or after the age of 70 has not yet been studied. Interestingly, in line with studies in other non-coding repeat expansion disorders, we showed that the repeat expansion leads to the formation of nuclear RNA foci, suggesting a possible toxic RNA gain-of-function disease mechanism. Our working hypothesis is that GGGGCC repeat expansions cause FTD and/or ALS, at least in part, through aberrant gene expression and alternative splicing changes that may result from the formation of these toxic RNA foci. The Specific Aims of this grant proposal are focused on 1) characterization of the variability in GGGGCC repeat size in blood, brain tissue and human cells in C9ORF72 mutation carriers and a detailed study of the effect of repeat size on clinical and pathological phenotypes; 2) identification of genetic modifiers of disease onset and/or presentation in patients carrying GGGGCC repeat expansions in C9ORF72; 3) study of the contribution of other GGGGCC repeats in the human genome to the development of FTD and ALS and 4) identification of gene expression and alternative splicing changes resulting from GGGGCC repeat expansions using high-throughput RNA sequencing in human brain tissue. The proposed studies are relevant to obtain a better understanding of the factors that contribute to the clinical and pathological variability associated with GGGGCC repeat expansions and have the ability to lead to the identification of mRNA targets implicated in FTD and ALS pathogenesis.
PUBLIC HEALTH RELEVANCE: This proposal is focused on the study of GGGGCC repeat expansions in C9ORF72, a novel common genetic cause of FTD and ALS. The proposed studies aim to provide a better understanding of the factors that contribute to the variable clinicl and pathological phenotypes seen in GGGGCC repeat carriers and have the ability to lead to the identification of mRNA targets implicated in FTD and ALS disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetics Core
-
批准号:9802930
-
项目类别:
-
资助金额:$57.49万
-
财政年份:2019
-
负责人:Rosa Rademakers
-
依托单位:
Genetics Core
-
批准号:10228129
-
项目类别:
-
资助金额:$1.76万
-
财政年份:2019
-
负责人:Rosa Rademakers
-
依托单位:
Genetics Core
-
批准号:10450020
-
项目类别:
-
资助金额:$54.54万
-
财政年份:2019
-
负责人:Rosa Rademakers
-
依托单位:
Genetics Core
-
批准号:10208705
-
项目类别:
-
资助金额:$54.54万
-
财政年份:2019
-
负责人:Rosa Rademakers
-
依托单位:
Whole genome sequencing consortium on Frontotemporal dementia with underlying TDP-43 pathology
-
批准号:9977807
-
项目类别:
-
资助金额:$121.38万
-
财政年份:2017
-
负责人:Rosa Rademakers
-
依托单位:
Whole genome sequencing consortium on Frontotemporal dementia with underlying TDP-43 pathology
-
批准号:10263328
-
项目类别:
-
资助金额:$121.39万
-
财政年份:2017
-
负责人:Rosa Rademakers
-
依托单位:
Whole genome sequencing consortium on Frontotemporal dementia with underlying TDP-43 pathology
-
批准号:9751999
-
项目类别:
-
资助金额:$122.78万
-
财政年份:2017
-
负责人:Rosa Rademakers
-
依托单位:
Genetic Discovery and Pathobiology of Frontotemporal Lobar Degeneration and Related TDP-43 Proteinopathies
-
批准号:9156742
-
项目类别:
-
资助金额:$88.86万
-
财政年份:2016
-
负责人:Rosa Rademakers
-
依托单位:
Molecular genetic studies of progranulin regulators in FTLD and ALS
-
批准号:8842721
-
项目类别:
-
资助金额:$34.23万
-
财政年份:2013
-
负责人:Rosa Rademakers
-
依托单位:
Molecular genetic studies of progranulin regulators in FTLD and ALS
-
批准号:8652520
-
项目类别:
-
资助金额:$33.89万
-
财政年份:2013
-
负责人:Rosa Rademakers
-
依托单位:
Molecular genetic studies of progranulin regulators in FTLD and ALS
-
批准号:9058616
-
项目类别:
-
资助金额:$34.23万
-
财政年份:2013
-
负责人:Rosa Rademakers
-
依托单位:
Molecular genetic studies of progranulin regulators in FTLD and ALS
-
批准号:8498854
-
项目类别:
-
资助金额:$34.23万
-
财政年份:2013
-
负责人:Rosa Rademakers
-
依托单位:
GGGGCC hexanucleotide repeat expansions in neurodegenerative disease
-
批准号:8694115
-
项目类别:
-
资助金额:$35.97万
-
财政年份:2012
-
负责人:Rosa Rademakers
-
依托单位:
GGGGCC hexanucleotide repeat expansions in neurodegenerative disease
-
批准号:8550156
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2012
-
负责人:Rosa Rademakers
-
依托单位:
GGGGCC hexanucleotide repeat expansions in neurodegenerative disease
-
批准号:9107523
-
项目类别:
-
资助金额:$15.2万
-
财政年份:2012
-
负责人:Rosa Rademakers
-
依托单位:
Identification of novel Parkinsonian genes by wholegenome
-
批准号:8440411
-
项目类别:
-
资助金额:$31.49万
-
财政年份:2010
-
负责人:Rosa Rademakers
-
依托单位:
Identification of novel Parkinsonian genes by wholegenome
-
批准号:8724251
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2010
-
负责人:Rosa Rademakers
-
依托单位:
Identification of novel Parkinsonian genes by wholegenome
-
批准号:8550143
-
项目类别:
-
资助金额:$30.17万
-
财政年份:2010
-
负责人:Rosa Rademakers
-
依托单位:
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATION
-
批准号:7624825
-
项目类别:
-
资助金额:$17.99万
-
财政年份:2009
-
负责人:Rosa Rademakers
-
依托单位:
Progranulin: Mutation and Regulation in Neurodegenerative disease
-
批准号:8097995
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2009
-
负责人:Rosa Rademakers
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: